Q3 Loss Narrower Than Expected at 4 Cents, But Revenue Drops 39% and Misses
FOCL has more than doubled off its 52-week low of $1.82.
Summary
Q3 adjusted loss came in at 4 cents per ADS, far better than the 25-cent loss five analysts expected, and the reported net loss was $4.46 million. The problem is the top line: revenue fell 39.4% to $9.83 million against a $12.64 million consensus, a wide miss. That revenue shortfall is the number that matters for a company this small, since the loss beat is largely a cost and non-cash item story rather than a demand story. The stock had already fallen 2.9% this quarter and is up 31.9% year to date, so the revenue miss lands on a name that has run. Consensus rating is still buy with a $10 median price target, but the estimate trend has been down, with the mean earnings estimate off about 2.9% over three months.
At the time of this announcement, FOCL was trading at $3.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162.7M. The 52-week trading range was $1.82 to $6.40. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.